Education
About Us
Working with TipRanks
Follow Us
InterCure (IL:INCR)
:INCR
INCR Stock Chart & Stats
514.20
>-0.01(-0.10%)
At close: 4:00 PM EST
514.20
>-0.01(-0.10%)
Day’s Range― - ―
52-Week Range284.00 - 644.90
Previous CloseN/A
Volume249.40K
Average Volume (3M)91.19K
Market Cap
₪158.52M
Enterprise Value291.61M
Total Cash (Recent Filing)₪51.58M
Total Debt (Recent Filing)₪179.34M
Price to Earnings (P/E)―
Beta1.19
Next Earnings
Apr 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.60
Shares Outstanding54,681,335
10 Day Avg. Volume173,192
30 Day Avg. Volume91,185
Financial Highlights & Ratios
PEG Ratio-0.43
Price to Book (P/B)0.65
Price to Sales (P/S)1.09
P/FCF Ratio-3.64
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Vertical IntegrationOwning cultivation, production and distribution creates durable control over product quality, supply consistency and pricing. This vertical model can sustain gross margins, lower unit costs over time, and protect against third-party supply disruptions as the company scales domestically and abroad.
Market Leadership In Medical CannabisA leading position in Israel and presence in other jurisdictions provides structural advantages: regulatory expertise, brand recognition with patients and providers, and preferential access to limited licensing. These traits support durable demand and a platform for measured international expansion.
Partnerships And Diversified Revenue StreamsEstablished partnerships with providers and pharmacies create repeat demand and lower customer acquisition costs, while research collaborations and potential licensing offer non-sales revenue and product pipeline optionality. Diversified streams reduce reliance on a single channel long-term.
Bears Say
Declining Revenue And Negative MarginsSustained declines in revenue and compressing gross and operating margins indicate structural demand or cost issues. Persistent unprofitability erodes retained earnings, limits reinvestment capacity, and weakens competitive positioning versus better-funded peers over the medium term.
Negative Operating And Free Cash FlowOngoing negative operating and free cash flow signals cash burn and operational inefficiency. This reduces financial flexibility to invest in cultivation, R&D or geographic expansion, and increases dependency on external financing which can dilute shareholders or raise leverage over time.
Shrinking Equity And Moderate LeverageDecreasing shareholders' equity alongside existing leverage weakens the balance sheet buffer against shocks and limits capacity for capital-intensive expansion. Combined with losses, this raises long-term solvency and refinancing risk, potentially increasing future financing costs.
Intercure News
INCR FAQ
What was InterCure’s price range in the past 12 months?
InterCure lowest stock price was 284.00 and its highest was 644.90 in the past 12 months.
What is InterCure’s market cap?
InterCure’s market cap is ₪158.52M.
When is InterCure’s upcoming earnings report date?
InterCure’s upcoming earnings report date is Apr 30, 2026 which is in 85 days.
How were InterCure’s earnings last quarter?
InterCure released its earnings results on Oct 08, 2025. The company reported -3.6 earnings per share for the quarter, missing the consensus estimate of N/A by -3.6.
Is InterCure overvalued?
According to Wall Street analysts InterCure’s price is currently Overvalued.
Does InterCure pay dividends?
InterCure does not currently pay dividends.
What is InterCure’s EPS estimate?
InterCure’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does InterCure have?
InterCure has 54,681,335 shares outstanding.
What happened to InterCure’s price movement after its last earnings report?
InterCure reported an EPS of -3.6 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.739%.
Which hedge fund is a major shareholder of InterCure?
Currently, no hedge funds are holding shares in IL:INCR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Intercure Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Company Description
InterCure
InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Israel and internationally. It offers dried cannabis inflorescences and cannabis extract mixed with oil. The company also invests in biomed sector. InterCure Ltd. was incorporated in 1994 and is headquartered in Herzliya, Israel.